Navigation Links
Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals
Date:12/22/2009

rop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='79877557';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.celltherapeutics.com/investors_alert">http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL as determined by the FDA (including ODAC), CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


    Media Contact:                       Investors Contact:

    Dan Eramian                          Ed Bell
    T: 206.272.4343                      T: 206.272.4345
    C: 206.854.1200                      Lindsey Jesch Logan
    F: 206.272.4434                      T: 206.272.4347
    E: 
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
2. Dennis Winger Joins Nektar Therapeutics Board of Directors
3. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
4. Oxford BioTherapeutics Appoints Michael Moore as Chairman
5. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
6. Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
7. Pearl Therapeutics Appoints Howie Rosen to Board of Directors
8. Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
9. Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
10. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
11. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Drug ... plant-derived compounds. BCC Research reveals in its new report that the U.S. ... defines the category and generates the most market demand. , BCC Research ...
(Date:9/2/2015)... , Sept. 2, 2015 Veracyte, Inc. ... H. Anderson , president and chief executive officer, will ... Wednesday, September 16, 2015 at 10:30 a.m. ET in ... The live audio webcast and subsequent replay may ... webcast will be available shortly after conclusion of the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in ... surgeries. From vital sign monitoring in ICU to 3D skull printing analysis for ... make real-time clinical decisions with simultaneous access to high precision medical images and ...
(Date:9/2/2015)... ... 2015 , ... Genedata, a leading provider of advanced software ... ® version 13.0 at ELRIG Drug Discovery 2015. This latest version of the ... new capabilities. Screener now supports High Throughput Flow Cytometry (HT-Flow) and Drug Metabolism ...
Breaking Biology Technology:Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... Upregulation by Percutaneous Administration of Gene Therapy in ... Effects of SERCA2a Enzyme Replacement Using Gene TransferSAN ... the publication of results from a Phase 1/2 ... replacement therapy for advanced heart failure, in the ...
... a DNA sequencing technology company, announced a definitive ... equity investment in the company. Prompting its decision ... novel reversible terminator chemistry, Lightning Terminators (TM), ... its chemistry as reagent kits to the market ...
... Inc. announced today that it has entered into ... NYSE: SNY ), providing the global ... platform for the research, development and commercialization of ... (ADCC). "We are extremely pleased about our partnership ...
Cached Biology Technology:The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure 2The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure 3SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM) 2BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis 2
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/10/2015)... The latest 364 page report from business intelligence ... border security market . Visiongain assesses that ... Now: Border security is hard to achieve and harder ... issue you need to know about - and more importantly, ... how this will impact your company and the border security ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... of Medicine researchers have discovered how the membrane protein ... this protein becomes desensitized so that one no longer ... an advance online publication by Nature Neuroscience, focused on ... found in many other receptors, including ones involved in ...
... self-replicating, mineralizing agent, has been identified by National Aeronautics ... in kidney stone formation among astronauts. With the potential ... Mars, longer missions, and exposure to the elements of ... , To further comprehend the implications of NB, trials ...
... sclerosis (MS) can be an unpredictable disease. It ... nerve cells and disrupts normal nerve signaling. Patients ... pain, fatigue, and blurred vision—that can appear independently ... appear in no particular order, flare-ups are common ...
Cached Biology News:Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients 2
... versatile ST-195 allows real-time observations of cell ... instrument has 64 different strain parameters in ... The thin silicon strain chamber used by ... and fluorescence microscopy. ST-195 can be used ...
... biologic production demands on cell and tissue ... cell populations. Therefore, both cell concentration and ... accurately and precisely. The new Vi-CELLTM Cell ... effective means to perform the trypan blue ...
... The Mini Trans-Blot cell and PowerPac Basic ... gels to membranes. The Mini Trans-Blot cell accommodates ... 2 gel holder cassettes, modular electrode assembly, Bio-Ice ... and 4 fiber pads. The PowerPac basic power ...
...
Biology Products: